Series
Most Recent Segment
CEO Connect
Featuring SENTI Bio
January 14, 2026
Timothy Lu, MD, PhD, CEO of Senti, discusses its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including AML.
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
CEO Corner
Featuring Autonomix
December 23, 2025
Brad Hauser, CEO of Autonomix, outlines two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.
What This Means
Featuring Akari Therapeutics
December 18, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics highlights the recently announced new preclinical data that demonstrates the therapeutic potential of Akari’s lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer.
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
Featuring American Resources
December 8, 2025
Mark Jensen, Executive Chairman of American Resources and CEO of ReElement Technologies, and Jacob Clayton, CEO of SAGINT Inc., discuss the strategic collaboration between the companies to implement blockchain-based tokenization for global critical mineral traceability and transparency.
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
Featuring HCW Biologics
October 22, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
What This Means
Featuring HCW Biologics
September 30, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
What This Means
Featuring enVVeno Medical
September 26, 2025
Rob Berman, CEO discusses the Company’s recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
What This Means
Featuring Nuwellis, Inc.
September 17, 2025
Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT).
What This Means
Featuring Autonomix
September 4, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and 100% zero opioid use.
KOL Connect
Featuring Palisade Bio
August 25, 2025
Moderated discussion with leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
What This Means
Featuring Senti Biosciences
August 12, 2025
Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company’s recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy, SENTI-202, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
What This Means
Featuring Sonnet BioTherapeutics
August 11, 2025
Dr. Richard Kenney, Chief Medical Officer of Sonnet discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
What This Means
Featuring enVVeno Medical
August 4, 2025
Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discuss the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval.
What This Means
Featuring GRI Bio
July 31, 2025
Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discusses the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”).